Organon price target raised to $26 from $25 at Barclays

Barclays raised the firm’s price target on Organon to $26 from $25 and keeps an Overweight rating on the shares. The analyst thinks Organon “provided as emphatic a defense as possible” on generic threats and the durability of Nexplanon, which the firm says could set to rest long-term concerns. It increased estimates post the Q4 report.